ClinicalTrials.gg
Not yet recruitingNCT07504393Updated Mar 31, 2026

Clinical Performance of Four Restorative Materials in Primary Molars

An interventional study of Cention N and Stela, SDI, Australia in Dental Caries and Primary Molars, sponsored by Al-Azhar University. Not yet recruiting. Open to participants aged 4 Years to 8 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
4 Years to 8 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Dental Caries by Al-Azhar University — 3 open to participants now, 5 under way, none of them phase 3. Dental Caries · Al-Azhar University.

Planned enrollment
Largest of 16
92 · median 36
Started
2026
the only one that year
No phase
16 of 17
2 open now
Registered
17th of 17
by date

Among the 17 studies in Dental Caries by Al-Azhar University, this one has the largest planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 16 with no phase, and was the 17th registered.

Dental Caries

1,176 studies on the registry are indexed under Dental Caries; 209 are open to participants now.

Browse Dental Caries studies →

Open to participants now

3 of the 17 studies in Dental Caries by Al-Azhar University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.

This study: 4 Years to 8 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Dental Caries by Al-Azhar University, or all of them as a file.
02

Study summary

This randomized clinical trial aims to compare the clinical and radiographic performance of four direct restorative materials used for restoring carious primary molars in children. Eligible children aged 4-8 years with posterior primary molars requiring direct restoration will be randomly allocated (1:1:1:1) to receive one of the following materials: an alkasite restorative material (Cention N), a self-cure bulk-fill resin composite (Stela; SDI), a conventional light-cured nanohybrid resin composite (Beautifil II), or a resin-modified glass ionomer cement (Riva Light Cure). Restorations will be evaluated using the Fédération Dentaire Internationale (FDI) World Dental Federation criteria. Postoperative sensitivity will be assessed at 48 hours using a 0-10 visual analogue scale (VAS). Clinical and radiographic follow-up assessments will be conducted at baseline and at scheduled recall visits

03

Conditions studied

  • Dental Caries
  • Primary Molars

Browse trials for

Keywords

  • stela
  • Primary molars
  • Pediatric dentistry
  • Direct restoration
  • Cention N
  • Nanohybrid composite
  • Resin-modified glass ionomer
  • FDI criteria
04

Who can participate

Ages eligible
4 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 4-8 years old.
  2. Primary molars indicated for restorative treatment.
  3. No pulp involvement or history of dental pain.
  4. Cooperative children (Frankl: +ve or ++ve).

Exclusion criteria

Exclusion Criteria:

  1. Pulp exposure after caries removal or clinical signs of irreversible pulpitis/necrosis.
  2. Severe developmental enamel defects or insufficient enamel for bonding.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Group A: Cention N

    Device: Cention N

  • Experimental
    Group B: Stela (Self-cure Bulk-fill Composite)

    Device: Stela, SDI, Australia

  • Active comparator
    Group C: Beautifil II (Nanohybrid Composite)

    Device: Beautifil II, Shofu, Japan

  • Active comparator
    Group D: Riva Light Cure (RMGIC)

    Device: Resin modified glass ionomer cement

Interventions

  • DeviceCention N

    Alkasite restorative material (Cention N) used for direct restoration of carious primary molars according to the manufacturer's instructions.

    Also known as: Ivoclar Vivadent

  • DeviceStela, SDI, Australia

    Self-cure bulk-fill resin composite (Stela; SDI) used for direct restoration of carious primary molars according to the manufacturer's instructions.

  • DeviceBeautifil II, Shofu, Japan

    Light-cured nanohybrid resin composite (Beautifil II) used for direct restoration of carious primary molars according to the manufacturer's instructions.

  • DeviceResin modified glass ionomer cement

    Resin-modified glass ionomer cement (Riva Light Cure) used for direct restoration of carious primary molars according to the manufacturer's instructions.

06

What researchers measure

Primary outcomes

  1. Restoration success based on FDI criteria (clinical and radiographic evaluation)

    Time frame: 6 months

  2. Restoration success based on FDI criteria (clinical and radiographic evaluation)

    Clinical and radiographic success of restorations assessed using the Fédération Dentaire Internationale (FDI) World Dental Federation criteria (scores 1-5). Scores 1-3 are considered clinically acceptable; scores 4-5 are considered clinically unacceptable (repair or replacement indicated).

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — individual participant data will not be shared to protect participant privacy and confidentiality, in accordance with the informed consent provided by the participants and the ethical approval granted for this study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Oct 2026, 6 months later.

Of 470 non-industry interventional studies with no phase under Dental Caries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 6 months is below that.

Counting every sponsor, half of 503 studies reached it within 15 months; a quarter within 7 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 31, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Nov 2026
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07504393
Responsible party
Hosam Hassan (principal investigator, Al-Azhar University) — Principal investigator
First posted
Mar 31, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Oct 31, 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Mar 31, 2026

Study contacts

Hosam Hassan Metwalli
Contact
dr.hosamhassan2@gmail.com
+201147957878

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion